Marc Bircham and Tamer Hassan Lead the Charge for Sports.com at the Prestigious Soccerex Kickoff in Cairo, Egypt
The first event under this new partnership kicks off February 23 in Cairo, Egypt, launching a dynamic series of global soccer business and networking events. These events bring together industry leaders, clubs and players to shape the future of the sport.
Leading the charge for Sports.com at this prestigious Soccerex kickoff will be Marc Bircham, the former QPR and Millwall star, who now serves as the Director and Head of Football Acquisition at Sports.com. Bircham will be joined by Tamer Hassan, the internationally acclaimed Hollywood actor and Director at Lottery.com, best known for his standout performances in The Football Factory and The Business.
As part of their appearance at Soccerex MENA in Cairo, Marc Bircham and Tamer Hassan will host an exclusive Q&A session at the Soccerex Sports Expo on Sunday, February 23, offering attendees the opportunity to hear insights on the global soccer industry, their personal experiences in sports and entertainment, and the future vision of Sports.com's involvement in the game.
Following the 2025 kickoff event in Cairo, Egypt, Soccerex will host their next event in Amsterdam in May 2025 which will take place at the iconic Johan Cruyff Arena, one of Europe's most renowned soccer stadiums. During the Amsterdam and Miami events, Sports.com will host a number of private events, featuring international soccer coaches and managers from the Premier League. Additionally, special guests from other sports around the world will be in attendance, with a particular focus on motorsports.
The Miami event is scheduled for November 2025 and will be held at the prestigious Hard Rock Hotel Resort in Fort Lauderdale, promising a world-class experience that blends elite soccer networking with luxury hospitality.'I am incredibly excited to represent Sports.com at Soccerex and be part of this global journey. Soccerex is known for bringing together some of the biggest names and brightest minds in the football world, and I am looking forward to sharing my own experiences, both on and off the pitch. The lineup of events we have planned, especially with the incredible settings in Amsterdam and South Florida will provide unmatched opportunities for meaningful conversations about the future of the game. Sports.com is here to make a lasting impact and this partnership is only the beginning.' 'Soccer has always been a passion of mine, and to be part of Soccerex representing Sports.com is a real privilege. The beautiful game connects people from all walks of life, and Soccerex is the perfect platform to bring those connections to the forefront. With Sports.com, we are committed to creating unique opportunities that unite sports, entertainment and technology. From Cairo to Amsterdam and Miami, I am looking forward to the incredible journey ahead and the impact we are set to make.'
About Sports.com
Sports.com is a premier digital sports platform dedicated to delivering cutting-edge content, fan engagement and technological innovation in the sports industry. With a commitment to growing the global soccer ecosystem, Sports.com partners with leading organizations and influencers to create unparalleled experiences for fans and professionals alike.
Important Notice Regarding Forward-Looking Statements
This press release contains statements that constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included in this press release, regarding the Company's strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. When used in this Form 8-K, the words 'could,' 'should,' 'will,' 'may,' 'believe,' 'anticipate,' 'intend,' 'estimate,' 'expect,' 'project,' 'initiatives,' 'continue,' the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management's current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. The forward-looking statements speak only as of the date of this press release or as of the date they are made. The Company cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of the Company. In addition, the Company cautions you that the forward-looking statements contained in this press release are subject to risks and uncertainties, including but not limited to, any future findings from ongoing review of the Company's internal accounting controls, additional examination of the preliminary conclusions of such review, the Company's ability to secure additional capital resources, the Company's ability to continue as a going concern, the Company's ability to respond in a timely and satisfactory matter to the inquiries by Nasdaq, the Company's ability to regain compliance with the Bid Price Requirement, the Company's ability to regain compliance with Nasdaq Listing Rules, the Company's ability to become current with its SEC reports, and those additional risks and uncertainties discussed under the heading 'Risk Factors' in the Form 10-K/A filed by the Company with the SEC on June 14, 2024, and the other documents filed, or to be filed, by the Company with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that the Company has filed and will file from time to time with the SEC. These SEC filings are available publicly on the SEC's website at www.sec.gov. Should one or more of the risks or uncertainties described in this press release materialize or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release.
This press release was published by a CLEAR® Verified individual.
CONTACT: For more information, please visit www.lottery.com or contact our media relations team at press@lottery.com.Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Warren Buffett's Berkshire Hathaway Just Exited Its Stake in T-Mobile and Loaded Up on an Artificial Intelligence (AI) Infrastructure Stock That's Risen 7,850% Since Its IPO
Key Points Berkshire exited the large mobile carrier T-Mobile, despite the fact the company has been executing well. Berkshire also disclosed a few mystery stocks that it purchased in the first quarter but chose to keep confidential until recently. One stock Berkshire bought is a traditional commodity company positioned as an artificial intelligence infrastructure play. 10 stocks we like better than Nucor › Warren Buffett's company Berkshire Hathaway recently filed its 13F form with the Securities and Exchange Commission (SEC), disclosing what stocks the large conglomerate held at the end of the second quarter. Using these filings, investors can see what stocks Berkshire bought and sold in a three-month window and get a rare glimpse into the minds of some of the smartest investors in the world. Berkshire has been a bit muted in recent quarters, choosing to pile into cash. But the company did make some notable moves in the second quarter, selling one decent-sized position and loading up on an artificial intelligence (AI) infrastructure stock. After a strong year, Berkshire calls it quits on T-Mobile The one position that Berkshire completely exited in the quarter was in the large mobile carrier T-Mobile (NASDAQ: TMUS). The company sold its entire position that had been valued at over $1 billion. Based on filings, Berkshire initiated its position in T-Mobile toward the end of 2020, and appears to have done well on the stock, which is up over 120% in the past five years. T-Mobile has also had a strong 2025, with the stock up about 16.5% (as of Aug. 15), and it recently reported strong second-quarter earnings. Diluted earnings per share of $2.84 rose about 14% year over year, while revenue jumped nearly 7%. Meanwhile, the company achieved some of its best-ever customer growth in the quarter, including 12% growth in its 5G broadband customer base, which is among the best in the industry. In 2023, T-Mobile initiated a dividend, which it has already grown significantly, and management's goal is to grow the quarterly dividend 10% annually. The team at Berkshire may simply be choosing to sell T-Mobile high. The stock is not far off from all-time highs and is now trading at a fairly high forward price-to-earnings ratio above 23. That's toward the higher end of where it has historically traded in recent years, and well above peers. The company has earned the valuation but Berkshire may see it as fairly priced right now. Berkshire has been secretly buying this AI infrastructure stock Many investors came into this 13F season excited about Berkshire once they realized that it would unveil some mystery stocks. Funds can request permission from the SEC to keep certain positions confidential for a certain amount of time. So Berkshire actually purchased Nucor (NYSE: NUE) in the first quarter, but the market only just found out about it in the company's second-quarter 13F. Berkshire's position in Nucor amounted to over $850 million at the end of the second quarter. Nucor is a steel company at its core. However, AI investors have gotten very interested because Nucor makes steel parts for data centers, which are in high demand to power and store all of the necessary data for large language models and AI applications. As a result of this and the way Nucor is positioned to support other burgeoning sectors, the stock has ripped close to 215% over the past five years and is up about 27% this year. Nucor's earnings through the first six months of the year are down significantly compared to last year, as the costs to make its steel products have risen. Investors were also disappointed by management's third-quarter guidance calling for "nominally lower" earnings, mainly due to margin compression in some of its segments. But the market expects President Donald Trump's 50% steel tariffs to benefit U.S. steel companies like Nucor, which will have an easier time raising prices because steel manufactured in other countries will be less competitive and more expensive. However, it could take time for higher prices to roll through. Nucor trades at about 17.5 times forward earnings, which I wouldn't necessarily call cheap in the steel sector. However, we have seen Buffett and his team get interested in U.S.-based commodity companies like oil and gas, perhaps due to a belief in increasing demand over time and a finite supply. Nucor could fit into this theme. Do the experts think Nucor is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Nucor make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,070% vs. just 184% for the S&P — that is beating the market by 885.55%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Bram Berkowitz has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Berkshire Hathaway. The Motley Fool recommends T-Mobile US. The Motley Fool has a disclosure policy. Warren Buffett's Berkshire Hathaway Just Exited Its Stake in T-Mobile and Loaded Up on an Artificial Intelligence (AI) Infrastructure Stock That's Risen 7,850% Since Its IPO was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
Why Iovance Biotherapeutics Stock Was Climbing Today
Key Points Iovance secured conditional approval for its cancer drug in Canada. This is pending the outcome of late-stage clinical trials. 10 stocks we like better than Iovance Biotherapeutics › A piece of good news on the regulatory front and a subsequent bullish analyst update were the factors driving Iovance Biotherapeutics (NASDAQ: IOVA) stock higher on Tuesday. The shares were almost 6% in positive territory in the middle of today's trading session, contrasting very well with the 0.5% slide of the S&P 500 index. Canada's thumbs-up for Amtagvi Just after market close Monday, Iovance announced that its cancer drug Amtagvi had been conditionally approved in Canada for treatment of certain forms of unresectable or metastatic melanoma. This green light from Health Canada, the country's medical regulator, is the biotech's first approval outside its native U.S. Final approval is conditional upon the results of late-stage clinical trials being conducted by the company. It added that it expects to authorize its first specialized treatment center in Canada in order to administer the medicine. It intends to do this at some point in the coming months. Iovance hopes to win approvals for Amtagvi in other jurisdictions with high instances of advanced melanoma specifically, and solid-tumor cancers generally. The drug earned approval from the U.S. Food and Drug Administration (FDA) for a similar indication in February 2024. It was the first cellular therapy to get the FDA's nod. Positive momentum Tuesday morning, H.C. Wainwright analyst Joseph Pantginis reiterated his buy recommendation on Iovance and his $20 per share price target. Not surprisingly, Pantginis' update was focused on the Health Canada move, according to reports. He wrote that it could be something of an inflection point for the healthcare company because Amtagvi will start producing a new revenue stream after final approval and boost the chances of a green light in other jurisdictions. Do the experts think Iovance Biotherapeutics is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Iovance Biotherapeutics make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,076% vs. just 184% for the S&P — that is beating the market by 892.04%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Iovance Biotherapeutics. The Motley Fool has a disclosure policy. Why Iovance Biotherapeutics Stock Was Climbing Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
36 minutes ago
- Yahoo
Cisco (CSCO) Price Target Increased as Wall Street Sees AI Growth Ahead
Cisco Systems, Inc. (NASDAQ:CSCO) is one of the . On August 14, BofA Securities analyst Tal Liani raised the price target on the stock to $85.00 (from $76.00) while maintaining a Buy rating. According to the analysts, Cisco's Q4 results and FY26 guidance 'lacked a major spark,' but were slightly better than expectations. It further believes that Cisco's story is 'about a revamped portfolio, a significant infrastructure cycle driven by AI and data growth, and constant improvement in execution.' 'Cisco's tale is about a revamped portfolio, a significant infrastructure cycle driven by AI and data growth, and constant improvement in execution. The results/guidance lacked a major spark though were slightly better than expectations, with revenue growth of 7.6% YoY vs. Street's 7.3%, in-line margins, and a 1c beat to consensus EPS estimates of $0.98. However, they reflect steady improvement on most fronts, including 10% order growth, excluding the weak Federal segment, strong networking trends, and recovery in Security growth.' While we acknowledge the potential of CSCO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
